Smith & Nephew (NYSE:SNN)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity in a report issued on Friday. They presently have a $45.00 price target on the medical equipment provider’s stock. Canaccord Genuity’s price objective would suggest a potential upside of 30.13% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on SNN. Zacks Investment Research cut Smith & Nephew from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Morgan Stanley cut Smith & Nephew from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $44.00.

Smith & Nephew (SNN) traded down $0.25 during trading on Friday, reaching $34.58. The company’s stock had a trading volume of 336,800 shares, compared to its average volume of 604,033. The company has a quick ratio of 1.08, a current ratio of 2.18 and a debt-to-equity ratio of 0.38. Smith & Nephew has a one year low of $29.76 and a one year high of $40.43.

Several hedge funds have recently bought and sold shares of SNN. Crossmark Global Holdings Inc. bought a new stake in Smith & Nephew during the third quarter valued at about $12,640,000. Jane Street Group LLC increased its stake in Smith & Nephew by 109.1% in the 3rd quarter. Jane Street Group LLC now owns 340,327 shares of the medical equipment provider’s stock valued at $12,388,000 after buying an additional 177,546 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Smith & Nephew by 17.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 516,794 shares of the medical equipment provider’s stock valued at $18,811,000 after buying an additional 76,003 shares during the last quarter. Blue Jay Capital Management LLC acquired a new stake in Smith & Nephew in the 2nd quarter valued at $6,970,000. Finally, FDx Advisors Inc. increased its stake in Smith & Nephew by 39.5% in the 3rd quarter. FDx Advisors Inc. now owns 27,490 shares of the medical equipment provider’s stock valued at $1,001,000 after buying an additional 7,790 shares during the last quarter. Institutional investors and hedge funds own 6.39% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Reiterates “Buy” Rating for Smith & Nephew (SNN)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/canaccord-genuity-reiterates-buy-rating-for-smith-nephew-snn.html.

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.